J.P. Morgan analyst Daniel Kerven maintained a Buy rating on RELX plc (RLXXF – Research Report) today and set a price target of £42.50.
MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces a ...
Seniors age 75 will lose on average more than four years of life if they keep smoking, compared to people who never smoked, ...
After hours: October 14 at 5:04 PM EDT Loading Chart for ICLR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback